Concomitant Use of SPRAVATO With Antidepressant Monotherapy or Augmentation Therapy in Clinical Trials in Major Depressive Disorder and Suicidal Ideation with Intent
![J&J scores Spravato trial win in high-risk depression. Will doctors and payers buy in? | Fierce Pharma J&J scores Spravato trial win in high-risk depression. Will doctors and payers buy in? | Fierce Pharma](https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1568071843/spravato.jpg/spravato.jpg?VersionId=0Xm8XJLxyUxH8mm1UQ1Vm8Q8W.8is_ui)
J&J scores Spravato trial win in high-risk depression. Will doctors and payers buy in? | Fierce Pharma
![Janssen Announces U.S. FDA Approval of SPRAVATO™ (esketamine) CIII Nasal Spray for Adults with Treatment-Resistant Depression (TRD) Who Have Cycled Through Multiple Treatments Without Relief Janssen Announces U.S. FDA Approval of SPRAVATO™ (esketamine) CIII Nasal Spray for Adults with Treatment-Resistant Depression (TRD) Who Have Cycled Through Multiple Treatments Without Relief](https://mma.prnewswire.com/media/831191/Janssen_Spravato.jpg)
Janssen Announces U.S. FDA Approval of SPRAVATO™ (esketamine) CIII Nasal Spray for Adults with Treatment-Resistant Depression (TRD) Who Have Cycled Through Multiple Treatments Without Relief
![Janssen Announces U.S. FDA Approval of SPRAVATO® (esketamine) CIII Nasal Spray to Treat Depressive Symptoms in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior Janssen Announces U.S. FDA Approval of SPRAVATO® (esketamine) CIII Nasal Spray to Treat Depressive Symptoms in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior](https://mma.prnewswire.com/media/1222649/Janssen_Pharmaceutical_Companies_of_Johnson_and_Johnson_Logo.jpg?p=facebook)
Janssen Announces U.S. FDA Approval of SPRAVATO® (esketamine) CIII Nasal Spray to Treat Depressive Symptoms in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior
![SPRAVATO® (esketamine) CIII Nasal Spray: The First and Only N-Methyl D-Aspartate (NMDA) Receptor Antagonist Approved in Conjunction With an Oral Antidepressant for the Treatment of Adults With Treatment-Resistant Depression | Psychiatrist.com SPRAVATO® (esketamine) CIII Nasal Spray: The First and Only N-Methyl D-Aspartate (NMDA) Receptor Antagonist Approved in Conjunction With an Oral Antidepressant for the Treatment of Adults With Treatment-Resistant Depression | Psychiatrist.com](https://www.psychiatrist.com/wp-content/uploads/2021/06/JA18039graphic1.gif)
SPRAVATO® (esketamine) CIII Nasal Spray: The First and Only N-Methyl D-Aspartate (NMDA) Receptor Antagonist Approved in Conjunction With an Oral Antidepressant for the Treatment of Adults With Treatment-Resistant Depression | Psychiatrist.com
![Spravato 28 mg nasal spray, solution - Summary of Product Characteristics (SmPC) - print friendly - (emc) Spravato 28 mg nasal spray, solution - Summary of Product Characteristics (SmPC) - print friendly - (emc)](https://www.medicines.org.uk/emc/images/spc/spc~37360~4~185061A.png)
Spravato 28 mg nasal spray, solution - Summary of Product Characteristics (SmPC) - print friendly - (emc)
![SPRAVATO®▽ (Esketamine) Nasal Spray Approved in Europe for Adults with Treatment-Resistant Major Depressive Disorder | Business Wire SPRAVATO®▽ (Esketamine) Nasal Spray Approved in Europe for Adults with Treatment-Resistant Major Depressive Disorder | Business Wire](https://mms.businesswire.com/media/20191219005272/en/764047/4/WebReady480.jpg)